Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 181-188

  Messersmith, Wells A ^a   Jimeno, Antonio ^b   Ettinger, David ^b   Laheru, Dan ^b   Brahmer, Julie ^b   Lansey, Dina ^b   Khan, Yasmin ^b   Donehower, Ross C ^b   Elsayed, Yusri ^c   Zannikos, Peter ^c   Hidalgo, Manuel ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dose finding; Gemcitabine; Pharmacokinetics; Phase I; Trabectedin

Indexed keywords

2' DEOXY 2',2' DIFLUOROURIDINE; FLUOROURIDINE; GEMCITABINE; TRABECTEDIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE CALCULATION; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HEART FAILURE; HUMAN; KIDNEY CANCER; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HEPATITIS, TOXIC; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TETRAHYDROISOQUINOLINES;

EID: 53149133906     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0733-7     Document Type: Article

References (40)

1. JY Blay M von Mehren BL Samuels 2007 Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): safety and efficacy analysis J Clin Oncol 25 18s (Abstr 10078)
2. Chu QSC, Schwartz G, Forouzesh B et al (2004) Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer. Presented at the 2004 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 28 September-1 October, Geneva, Switzerland
3. RB Cohen RJ Schilder J Cheng 2005 Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies J Clin Oncol 23 16s (Abstract 3074)
4. G Damia S Silvestri L Carrassa 2001 Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways Int J Cancer 92 583 588
5. S Donald RD Verschoyle P Greaves 2003 Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat Cancer Res 63 5902 5908
6. Fetterly GJ, Owen JS, Stuychens K et al (2007) Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectidin (ET-743) treatment. Cancer Chemother Phamacol, 9 October (Epub ahead of print)
7. R Garcia-Carbonero JG Supko RG Maki 2005 Ecteinascidin-743 for chemotherapy-naïve patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol 23 5484 5492
8. R Garcia-Carbonero JG Supko J Manola 2004 Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 1480 1490
9. L Gore E Rivera K LaVallee 2006 Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies J Clin Oncol 24 18s (Abstract 2079)
10. F Grosso RL Jones GD Demetri 2007 Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncol 8 595 602
11. JS Gurtler L Goldstein S Delprete 2005 Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens J Clin Oncol 23 16s (Abstract 625)
12. HR Hendriks HH Fiebig R Giavazzi 1999 High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer Ann Oncol 10 1233 1240
13. ML Hensley R Maki E Venkatraman 2002 Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J Clin Oncol 20 2824 2831
14. E Izbicka R Lawrence E Raymond 1998 In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients Ann Oncol 9 981 987
15. D Karacetin O Incekara 2006 Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer J BUON 11 181 184
16. C Laverdiere EA Kolb JG Supko 2003 Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma Cancer 98 832 840
17. A Le Cesne JY Blay I Judson 2005 Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial J Clin Oncol 23 576 584
18. WW Li N Takahashi S Jhanwar 2001 Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent Clin Cancer Res 7 2908 2911
19. KY Look A Sandler JA Blessing 2004 Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study Gynecol Oncol 92 644 647
20. RG Maki JK Wathen SR Patel 2007 Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through study 002 J Clin Oncol 25 2755 2763
21. DS McMeekin C Krasner S Chan 2005 Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma J Clin Oncol 23 16s (Abstract 5011)
22. D Meco T Colombo P Ubezio 2003 Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies Cancer Chemother Pharmacol 52 131 138
23. O Merimsky I Meller G Flusser 2000 Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II trial Cancer Chemother Pharmacol 45 177 181
24. M Minuzzo S Marchini M Broggini 2000 Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743 Proc Natl Acad Sci 97 6780 6784
25. BM Moore FC Seaman RT Wheelhouse 1998 Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2 J Am Chem Soc 120 2490 2491
26. JA Morgan A Le Cesne S Chawla 2007 Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma(L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I) J Clin Oncol 25 18s (Abstract 10060)
27. Y Pommier G Kohlhagen C Bailly 1996 DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata Biochemistry 35 13303 13309
28. TA Puchalski DP Ryan R Garcia-Carbonero 2002 Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity Cancer Chemother Pharmacol 50 309 319
29. K Scotlandi S Perdichizzi MC Manara 2002 Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells Clin Cancer Res 8 3893 3903
30. C Sessa F DeBraud A Perotti 2005 Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails J Clin Oncol 23 1867 1874
31. CH Spiridonidis LR Laufman J Jones 1998 Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies J Clin Oncol 16 3866 3873
32. W Sun JP Stevenson M Gallagher 2001 A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors Cancer 92 414 419
33. N Takahashi WW Li D Banerjee 2001 Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells Clin Cancer Res 7 3251 3257
34. N Takahashi WW Li D Banerjee 2002 Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo Cancer Res 62 6909 6915
35. Y Takebayashi P Pourquier DB Zimonjic 2001 Antiproliferative acitivty of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat Med 7 961 966
36. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216
37. G Valoti MI Nicoletti A Pellegrino 1998 Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts Clin Cancer Res 4 1977 1983
38. MA Villalona-Calero SG Eckhardt G Weiss 2002 A phase I and pharmacokinetic study of ecteinascidin-743 on a daily ×5 schedule in patients with solid malignancies Clin Cancer Res 8 75 85
39. A Yovine M Riofrio JY Blay 2004 Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol 22 890 899
40. ® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer Br J Cancer 94 1610 1614